1. Phylogeny  
   Serine/threonine‐protein kinase mTOR is a highly conserved member of the phosphatidylinositol 3‐kinase‐related kinase (PIKK) family that can be traced across eukaryotes. In yeast, orthologs exist as TOR1 and TOR2, which fulfill overlapping but distinct roles in regulating growth, ribosome biogenesis, and cytoskeletal organization (inoki2005signalingbytarget pages 1-1). In mammals, mTOR is encoded by a single gene yet retains the core functions inherited from the common ancestor of eukaryotes, including integration of nutrient, growth factor, and energy signals. mTOR belongs to an evolutionary core set of proteins that includes other key regulators such as Rheb, TSC1/TSC2, and components of the TOR complex (inoki2005signalingbytarget pages 1-3, inokiUnknownyearsignalingbytarget pages 3-4). Its phylogenetic grouping in the human kinome places it among the atypical serine/threonine kinases with a catalytic structure more similar to lipid kinases, although mTOR itself lacks lipid kinase activity. This subgroup derives from the early-branching evolutionary events that provided the regulatory backbone for cell growth and metabolism in all eukaryotes (inoki2005signalingbytarget pages 1-1).
2. Reaction Catalyzed  
   mTOR catalyzes the ATP-dependent phosphorylation reaction in which the γ-phosphate of ATP is transferred to specific serine or threonine residues located on substrate proteins. The chemical reaction can be represented as follows: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(phospho-L-serine or phospho-L-threonine) + H⁺. This reaction underpins the kinase’s ability to modulate the activity, localization, and interaction of multiple downstream targets (inoki2005signalingbytarget pages 5-6).
3. Cofactor Requirements  
   For its catalytic activity, mTOR requires divalent metal ions that facilitate the binding of ATP and the subsequent phosphoryl transfer reaction. Consistent with other serine/threonine kinases, mTOR’s kinase activity is dependent on the presence of Mg²⁺ ions, and in some instances, Mn²⁺ may also serve as a cofactor. These metal ions coordinate the ATP substrate within the catalytic pocket, enabling the efficient transfer of the phosphate group to substrate proteins (inoki2005signalingbytarget pages 10-11, sabbah2011dualinhibitorsof pages 15-16).
4. Substrate Specificity  
   mTOR displays substrate specificity that is governed by the linear amino acid context flanking the phosphorylated serine/threonine residue. Recent large-scale studies have refined the consensus phosphorylation motifs recognized by mTOR complexes. Specifically, analysis from Johnson et al. (2023) provides evidence that mTOR substrates tend to possess particular amino acid preferences around the phospho-acceptor site; these preferences include basophilic determinants that likely involve positively charged residues proximal to the target site (johnson2023anatlasof pages 3-4, johnson2023anatlasof pages 12-18). In mTORC1, substrates such as 4E-BP1 and RPS6KB1 (p70 S6 kinase) exhibit motifs that promote interaction with mTOR through docking sequences like the TOR signaling (TOS) motif, characterized by a short, conserved stretch of hydrophobic residues necessary for recruitment by adaptor proteins like Raptor (inoki2005signalingbytarget pages 5-6, inoki2005signalingbytarget pages 4-5). Although mTOR itself phosphorylates a broad array of downstream proteins—over 800 have been documented—the precise consensus motif may be refined in future studies; current evidence underscores the importance of specific flanking residues in determining mTOR-mediated phosphorylation events (johnson2023anatlasof pages 4-5).
5. Structure  
   mTOR is a very large protein with an elaborate multidomain organization that underlies both its catalytic and regulatory functions. The N-terminal region is characterized by multiple HEAT (Huntingtin, EF3, PP2A, TOR1) repeats that mediate extensive protein–protein interactions with regulatory adaptors and substrates. Following the HEAT repeats is the FAT (FRAP, ATM, TRRAP) domain, which is involved in the overall structural integrity and proper folding of the protein. Adjacent to this, mTOR contains the FRB (FKBP12-rapamycin binding) domain, whose binding to the FKBP12–rapamycin complex is responsible for the allosteric inhibition of mTORC1 by rapamycin. The central region houses the kinase domain, which is responsible for the ATP-dependent phosphorylation reaction; this catalytic core shows structural homology to phosphatidylinositol 3-kinases and contains key features such as the activation loop and a hydrophobic spine that is critical for catalytic competence (inoki2005signalingbytarget pages 3-4, inoki2005signalingbytarget pages 18-19). Finally, mTOR possesses a C-terminal FATC domain which is essential for maintaining the stability and activity of the kinase. High-resolution structural studies using crystallographic and cryo-electron microscopy approaches have begun to reveal conformational states of mTOR and its assemblies in mTORC1 and mTORC2, further highlighting the dynamic regulation of kinase activity by structural rearrangements and complex formation (inoki2005signalingbytarget pages 16-16, inokiUnknownyearsignalingbytarget pages 17-18).
6. Regulation  
   mTOR is subject to a complex network of regulatory mechanisms that finely tune its kinase activity in response to a variety of intracellular and extracellular signals. Key regulatory inputs include post-translational modifications such as phosphorylation events at multiple sites on mTOR and its associated regulatory proteins. For instance, phosphorylation by upstream kinases such as Akt and RSK is known to modulate mTOR activity, while feedback loops via downstream effectors like S6K can inhibit or activate upstream signaling components in a tightly controlled manner (inoki2005signalingbytarget pages 16-17, inokiUnknownyearsignalingbytarget pages 17-18). In addition to phosphorylation, mTOR is regulated through its assembly into two distinct multiprotein complexes—mTORC1 and mTORC2—with different regulatory subunits. The mTORC1 complex, which includes Raptor and mLst8, is acutely sensitive to nutrient levels, growth factors, and cellular energy status. Under conditions of nutrient sufficiency or growth factor stimulation, Rheb (a farnesylated small GTPase) becomes active and positively regulates mTORC1. Conversely, the TSC1/TSC2 complex, which functions as a GTPase-activating protein (GAP) for Rheb, acts as a major negative regulator when cellular conditions indicate stress or energy depletion (inoki2005signalingbytarget pages 15-16, inokiUnknownyearsignalingbytarget pages 15-16). In contrast, mTORC2 is primarily regulated by growth factor signaling and is largely insensitive to nutrient levels, thereby modulating cytoskeletal organization and survival pathways. In addition, mTOR regulation involves ubiquitination events and interactions with other regulatory proteins such as Rictor in mTORC2, and regulatory feedback via GRB10 that modulate insulin receptor signaling (inoki2005signalingbytarget pages 21-22). These layers of regulation ensure that mTOR integrates signals from multiple pathways—such as PI3K/Akt, AMPK, and LKB1—to maintain cellular homeostasis (inoki2005signalingbytarget pages 16-17).
7. Function  
   mTOR plays a central role in controlling cell growth, metabolism, and survival by coordinating processes that involve protein, lipid, and nucleotide synthesis. It is a master regulator of cellular anabolic processes that are critical for cell proliferation and growth. Under nutrient-rich conditions, mTORC1 is recruited to the lysosomal membrane where Rheb activates its kinase activity, leading to phosphorylation of pivotal downstream substrates such as 4E-BP1 and S6K1. Phosphorylation of 4E-BP1 results in its dissociation from the translation initiation factor eIF4E, thereby facilitating cap-dependent translation initiation. Concurrently, mTORC1-mediated phosphorylation of S6K1 and S6K2 stimulates the translation of mRNAs that encode components of the translational machinery, including proteins involved in ribosome biogenesis and elongation (inoki2005signalingbytarget pages 7-8, inoki2005signalingbytarget pages 8-9). In addition to protein synthesis, mTORC1 regulates lipid synthesis through its effects on sterol regulatory element-binding proteins (SREBPs) and influences nucleotide synthesis via both acute phosphorylation events (e.g., CAD phosphorylation mediated through RPS6KB1) and transcriptional control of the pentose phosphate pathway (inoki2005signalingbytarget pages 21-22). Moreover, mTOR plays a role in repressing autophagy by phosphorylating key autophagy regulators such as ULK1. This suppression of autophagy is a critical component of mTOR’s role in ensuring that anabolic processes proceed only under conditions of adequate nutrient availability (inoki2005signalingbytarget pages 21-22, inokiUnknownyearsignalingbytarget pages 17-18).  
   In mTORC2, which is less sensitive to nutrient levels, mTOR catalyzes the phosphorylation and subsequent activation of AGC family kinases including AKT, PKC isoforms, and SGK1. This arm of mTOR signaling contributes to the regulation of cell survival, proliferation, and the actin cytoskeleton (inoki2005signalingbytarget pages 20-20, inoki2005signalingbytarget pages 17-18). Together, the actions of mTOR in both complexes ensure the proper adjustment of cellular growth programs in response to a myriad of environmental cues, thereby linking extracellular signals with internal metabolic states (inoki2005signalingbytarget pages 17-18, inokiUnknownyearsignalingbytarget pages 22-23).
8. Other Comments  
   Pharmacological inhibition of mTOR has attracted extensive attention due to its critical role in oncogenesis, metabolic disorders, and other pathological conditions. Inhibitors such as rapamycin and its analogs (rapalogs) disrupt mTORC1 activity by binding to FKBP12 and interacting with the FRB domain of mTOR; these agents are currently in clinical use as immunosuppressants and anticancer therapies (sabbah2011dualinhibitorsof pages 9-10, inokiUnknownyearsignalingbytarget pages 17-18). In addition, ATP-competitive mTOR inhibitors have been developed to target both mTORC1 and mTORC2, thereby overcoming some limitations seen with rapamycin treatment that preferentially inhibits mTORC1 (sabbah2011dualinhibitorsof pages 11-12, sabbah2011dualinhibitorsof pages 16-16).  
   Disease associations related to mTOR dysregulation include various cancers, tuberous sclerosis complex, metabolic syndromes, and neurological disorders; mutations or aberrant signaling in upstream regulators such as PTEN, TSC1/TSC2, and Rheb are commonly linked to these conditions (yeo2018tumoursuppressortuberous pages 26-31, robak2005themammaliantarget pages 3-6). Moreover, mTOR’s involvement in feedback loops that modulate insulin signaling and metabolic reprogramming in cancer further highlights its importance as a therapeutic target. Known inhibitors currently under investigation include dual PI3K/mTOR inhibitors as well as mTOR-specific compounds, whose efficacy and selectivity continue to be evaluated in preclinical and clinical settings (sabbah2011dualinhibitorsof pages 13-14, robak2005themammaliantarget pages 12-15).
9. References  
   inoki2005signalingbytarget pages 1-1; inoki2005signalingbytarget pages 1-3; inokiUnknownyearsignalingbytarget pages 3-4; inoki2005signalingbytarget pages 5-6; inoki2005signalingbytarget pages 7-8; inoki2005signalingbytarget pages 8-9; inoki2005signalingbytarget pages 10-11; inoki2005signalingbytarget pages 16-16; inoki2005signalingbytarget pages 17-18; inoki2005signalingbytarget pages 20-20; inoki2005signalingbytarget pages 21-22; inokiUnknownyearsignalingbytarget pages 17-16; inokiUnknownyearsignalingbytarget pages 17-18; inokiUnknownyearsignalingbytarget pages 22-23; johnson2023anatlasof pages 3-4; johnson2023anatlasof pages 12-18; johnson2023anatlasof pages 4-5; johnson2023anatlasof pages 6-7; sabbah2011dualinhibitorsof pages 9-10; sabbah2011dualinhibitorsof pages 11-12; sabbah2011dualinhibitorsof pages 13-14; sabbah2011dualinhibitorsof pages 16-16; robak2005themammaliantarget pages 3-6; robak2005themammaliantarget pages 12-15; yeo2018tumoursuppressortuberous pages 26-31.

References

1. (sabbah2011dualinhibitorsof pages 15-16): D. Sabbah, M. Brattain, and Haizhen A. Zhong. Dual inhibitors of pi3k/mtor or mtor-selective inhibitors: which way shall we go? Current Medicinal Chemistry, 18:5528-5544, Dec 2011. URL: https://doi.org/10.2174/092986711798347298, doi:10.2174/092986711798347298. This article has 65 citations and is from a peer-reviewed journal.
2. (inoki2005signalingbytarget pages 1-1): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
3. (inoki2005signalingbytarget pages 1-3): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
4. (inoki2005signalingbytarget pages 10-11): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
5. (inoki2005signalingbytarget pages 16-16): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
6. (inoki2005signalingbytarget pages 17-18): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
7. (inoki2005signalingbytarget pages 18-19): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
8. (inoki2005signalingbytarget pages 20-20): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
9. (inoki2005signalingbytarget pages 3-4): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
10. (inoki2005signalingbytarget pages 4-5): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
11. (inoki2005signalingbytarget pages 5-6): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
12. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
13. (robak2005themammaliantarget pages 12-15): T Robak. The mammalian target of the rapamycin (mtor) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Unknown journal, 2005.
14. (robak2005themammaliantarget pages 3-6): T Robak. The mammalian target of the rapamycin (mtor) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Unknown journal, 2005.
15. (sabbah2011dualinhibitorsof pages 11-12): D. Sabbah, M. Brattain, and Haizhen A. Zhong. Dual inhibitors of pi3k/mtor or mtor-selective inhibitors: which way shall we go? Current Medicinal Chemistry, 18:5528-5544, Dec 2011. URL: https://doi.org/10.2174/092986711798347298, doi:10.2174/092986711798347298. This article has 65 citations and is from a peer-reviewed journal.
16. (sabbah2011dualinhibitorsof pages 13-14): D. Sabbah, M. Brattain, and Haizhen A. Zhong. Dual inhibitors of pi3k/mtor or mtor-selective inhibitors: which way shall we go? Current Medicinal Chemistry, 18:5528-5544, Dec 2011. URL: https://doi.org/10.2174/092986711798347298, doi:10.2174/092986711798347298. This article has 65 citations and is from a peer-reviewed journal.
17. (sabbah2011dualinhibitorsof pages 16-16): D. Sabbah, M. Brattain, and Haizhen A. Zhong. Dual inhibitors of pi3k/mtor or mtor-selective inhibitors: which way shall we go? Current Medicinal Chemistry, 18:5528-5544, Dec 2011. URL: https://doi.org/10.2174/092986711798347298, doi:10.2174/092986711798347298. This article has 65 citations and is from a peer-reviewed journal.
18. (sabbah2011dualinhibitorsof pages 9-10): D. Sabbah, M. Brattain, and Haizhen A. Zhong. Dual inhibitors of pi3k/mtor or mtor-selective inhibitors: which way shall we go? Current Medicinal Chemistry, 18:5528-5544, Dec 2011. URL: https://doi.org/10.2174/092986711798347298, doi:10.2174/092986711798347298. This article has 65 citations and is from a peer-reviewed journal.
19. (yeo2018tumoursuppressortuberous pages 26-31): SC Yeo. Tumour suppressor tuberous sclerosis complex 1 protein is decreased in the presence of veph1 in some cancer cell lines. Unknown journal, 2018.
20. (inoki2005signalingbytarget pages 15-16): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
21. (inoki2005signalingbytarget pages 16-17): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
22. (inoki2005signalingbytarget pages 21-22): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
23. (inoki2005signalingbytarget pages 7-8): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
24. (inoki2005signalingbytarget pages 8-9): Ken Inoki, Hongjiao Ouyang, Yong Li, and Kun-Liang Guan. Signaling by target of rapamycin proteins in cell growth control. Microbiology and Molecular Biology Reviews, 69:79-100, Mar 2005. URL: https://doi.org/10.1128/mmbr.69.1.79-100.2005, doi:10.1128/mmbr.69.1.79-100.2005. This article has 463 citations and is from a domain leading peer-reviewed journal.
25. (inokiUnknownyearsignalingbytarget pages 15-16): K Inoki, H Ouyang, and KL Guan. Signaling by target of rapamycin proteins. Unknown journal, Unknown year.
26. (inokiUnknownyearsignalingbytarget pages 17-18): K Inoki, H Ouyang, and KL Guan. Signaling by target of rapamycin proteins. Unknown journal, Unknown year.
27. (inokiUnknownyearsignalingbytarget pages 22-23): K Inoki, H Ouyang, and KL Guan. Signaling by target of rapamycin proteins. Unknown journal, Unknown year.
28. (inokiUnknownyearsignalingbytarget pages 3-4): K Inoki, H Ouyang, and KL Guan. Signaling by target of rapamycin proteins. Unknown journal, Unknown year.
29. (johnson2023anatlasof pages 12-18): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
30. (johnson2023anatlasof pages 4-5): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
31. (johnson2023anatlasof pages 6-7): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.